Deals

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC
AstraZenecaDizal Pharmaceutical

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA: 688192) announced that it has received a US$600 million upfront payment from AstraZeneca plc (NYSE: AZN), stemming from the global exclusive licensing agreement for…

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Vcare Pharma Partners with CTTQ Subsidiary to Commercialize Eratrectinib – Next‑Generation TRK Inhibitor Approved in China for NTRK Fusion Solid Tumors

Vcare Pharma Partners with CTTQ Subsidiary to Commercialize Eratrectinib – Next‑Generation TRK Inhibitor Approved in China for NTRK Fusion Solid Tumors

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Danaher Partners with Huashan Hospital to Develop Alzheimer's Diagnostic Solutions
Beckman Coulter Experimental SystemsDanaher

Danaher Partners with Huashan Hospital to Develop Alzheimer’s Diagnostic Solutions

Takeda to Establish China Innovation Center in Chengdu, Focusing on Digital Health
Healthcare Big DataNYSE: TAK

Takeda to Establish China Innovation Center in Chengdu, Focusing on Digital Health

NAMSA to Acquire WuXi AppTec's US Medical Device Testing Business
CRO / CMO / CDMOFinance

NAMSA to Acquire WuXi AppTec’s US Medical Device Testing Business

Xinzeyuan Medical Raises Series B+ Funding for Surgical Supply Chain
Xinzeyuan Medical Technology

Xinzeyuan Medical Raises Series B+ Funding for Surgical Supply Chain

Show More